HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients treated with felzartamab showed reductions in disease-linked biomarkers and stabilization of eGFR 63% (n=7/11)
/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Saturday, May 25, 2024/
OTTAWA, ON, May 24, 2024 /CNW/ – Note: All times local Greater Halifax Area, Nova Scotia 10:00 a.m. The Prime Minister will hold a roundtable with local community leaders. Note for media: Pooled photo opportunity This document is also available at https://pm.gc.ca SOURCE Prime Minister
PepsiCo Brands Lay’s® and Gatorade® Strengthen Commitment to Supporting Women in Sport in Celebration of UEFA Women’s Champions League Final
PepsiCo brands Lay’s® and Gatorade® unite in Bilbao, Spain, around the UEFA Women’s Champions League Final with programs that instill young female athletes with confidence and provide resources to fuel their participation in sport Lay’s RePlay unveils its 11th pitch in Bilbao, wi
Every vote counts: Manipal Hospital, Dwarka facilitates patient voting to strengthen democracy
NEW DELHI, May 25, 2024 /PRNewswire/ — Manipal Hospital took a significant step towards fostering civic responsibility by helping patients cast their votes in the Lok Sabha elections, ensuring they could exercise their right to vote. This effort underscores the hospital’s dedication to p
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3 Fabhalta showed a favorable safety profile with no new safety signals1 C3G, an ultra-rare
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to ele
We Must Respond to the Call by the African Union: Educate an Africa Fit for the 21st Century
Education Cannot Wait Executive Director Yasmine Sherif Statement on Africa Day 2024 NEW YORK, May 25, 2024 /PRNewswire/ — Africa is an amazingly beautiful continent with a powerful young generation who have the inherent right to an inclusive and continued quality education. Yet – and especi
Unlock an Exclusive Olympic Experience: Celebrating Live4Well’s Sold-Out Genesis NFT
HONG KONG, May 25, 2024 /PRNewswire/ — The buzz surrounding Live4Well’s successful Genesis NFT membership launch on May 23 has captivated both traditional and web3 communities. Combining the power of AI technology and decentralized physical infrastructure (DePin) concept, Live4Well has
CGTN: Eyeing Chinese modernization, China doubles efforts to further deepen reform on all fronts
BEIJING, May 25, 2024 /PRNewswire/ — Built after China’s reform and opening up, Rizhao Port in east China’s Shandong Province is a vital global hub for the transshipment of energy and bulk raw materials. Through recent technological innovation, the port has been upgraded into a mo
LINCOLN NATIONAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Lincoln National Corporation – LNC
NEW ORLEANS, May 24, 2024 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 24, 2024 to file lead plaintiff applications in a securities class action lawsuit aga
